These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 37005447)

  • 1. Targeting the NF-κB pathway enhances responsiveness of mammary tumors to JAK inhibitors.
    Bapat AS; O'Connor CH; Schwertfeger KL
    Sci Rep; 2023 Apr; 13(1):5349. PubMed ID: 37005447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. JAK/STAT inhibition in macrophages promotes therapeutic resistance by inducing expression of protumorigenic factors.
    Irey EA; Lassiter CM; Brady NJ; Chuntova P; Wang Y; Knutson TP; Henzler C; Chaffee TS; Vogel RI; Nelson AC; Farrar MA; Schwertfeger KL
    Proc Natl Acad Sci U S A; 2019 Jun; 116(25):12442-12451. PubMed ID: 31147469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.
    Zhao R; Hu Z; Zhang X; Huang S; Yu G; Wu Z; Yu W; Lu J; Ruan B
    Cell Commun Signal; 2024 Jan; 22(1):68. PubMed ID: 38273295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of the JAK/STAT signaling pathway in the pathogenesis of acute myocardial infarction in rats and its effect on NF-κB expression.
    Zhang S; Liu X; Goldstein S; Li Y; Ge J; He B; Fei X; Wang Z; Ruiz G
    Mol Med Rep; 2013 Jan; 7(1):93-8. PubMed ID: 23128561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting JAK/STAT signaling pathways in treatment of inflammatory bowel disease.
    Wang L; Hu Y; Song B; Xiong Y; Wang J; Chen D
    Inflamm Res; 2021 Jul; 70(7):753-764. PubMed ID: 34212215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the JAK/STAT Signaling Pathway for Breast Cancer.
    Shao F; Pang X; Baeg GH
    Curr Med Chem; 2021; 28(25):5137-5151. PubMed ID: 33290193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance.
    Sabaawy HE; Ryan BM; Khiabanian H; Pine SR
    Carcinogenesis; 2021 Dec; 42(12):1411-1419. PubMed ID: 34415330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.
    Ibrahim SSA; Salama MA; Selima E; Shehata RR
    Life Sci; 2020 Nov; 260():118261. PubMed ID: 32795539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule drug discovery targeting the JAK-STAT pathway.
    Lv Y; Mi P; Babon JJ; Fan G; Qi J; Cao L; Lang J; Zhang J; Wang F; Kobe B
    Pharmacol Res; 2024 Jun; 204():107217. PubMed ID: 38777110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK-STAT inhibition impairs K-RAS-driven lung adenocarcinoma progression.
    Mohrherr J; Haber M; Breitenecker K; Aigner P; Moritsch S; Voronin V; Eferl R; Moriggl R; Stoiber D; Győrffy B; Brcic L; László V; Döme B; Moldvay J; Dezső K; Bilban M; Popper H; Moll HP; Casanova E
    Int J Cancer; 2019 Dec; 145(12):3376-3388. PubMed ID: 31407334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quercetin as a JAK-STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases.
    Zalpoor H; Nabi-Afjadi M; Forghaniesfidvajani R; Tavakol C; Farahighasreaboonasr F; Pakizeh F; Dana VG; Seif F
    Cell Mol Biol Lett; 2022 Jul; 27(1):60. PubMed ID: 35883021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease.
    Talotta R
    Immunotherapy; 2021 Feb; 13(3):241-256. PubMed ID: 33410346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dunaliella salina alga extract inhibits the production of interleukin-6, nitric oxide, and reactive oxygen species by regulating nuclear factor-κB/Janus kinase/signal transducer and activator of transcription in virus-infected RAW264.7 cells.
    Lin HW; Liu CW; Yang DJ; Chen CC; Chen SY; Tseng JK; Chang TJ; Chang YY
    J Food Drug Anal; 2017 Oct; 25(4):908-918. PubMed ID: 28987368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Janus kinase inhibitors in dermatology: Part I. A comprehensive review.
    Chapman S; Kwa M; Gold LS; Lim HW
    J Am Acad Dermatol; 2022 Feb; 86(2):406-413. PubMed ID: 34246698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Emerging Role of Janus Kinase Inhibitors in the Treatment of Cancer.
    Karati D; Mahadik KR; Trivedi P; Kumar D
    Curr Cancer Drug Targets; 2022; 22(3):221-233. PubMed ID: 35232350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review.
    Huang IH; Chung WH; Wu PC; Chen CB
    Front Immunol; 2022; 13():1068260. PubMed ID: 36569854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Research Advances of JAK/STAT Signaling Pathway in Lung Cancer].
    Yang X; Tang Z; Zhang P; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Jan; 22(1):45-51. PubMed ID: 30674393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Potential of Janus Kinase Inhibitors for the Management of Interstitial Lung Disease.
    Huo R; Guo Q; Hu J; Li N; Gao R; Mi L; Zhang Z; Liu H; Guo Z; Zhao H; Zhang L; Xu K
    Drug Des Devel Ther; 2022; 16():991-998. PubMed ID: 35400994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antagonist of the JAK-1/STAT-1 signaling pathway improves the severity of cerulein-stimulated pancreatic injury via inhibition of NF-κB activity.
    Chen P; Huang L; Zhang Y; Qiao M; Yao W; Yuan Y
    Int J Mol Med; 2011 May; 27(5):731-8. PubMed ID: 21369693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Janus kinase inhibitors in autoimmune bullous diseases.
    Huang D; Zhang Y; Kong L; Lu J; Shi Y
    Front Immunol; 2023; 14():1220887. PubMed ID: 37492565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.